GO:1901223 negative regulation of non-canonical NF-kappaB signal transduction: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901223 describes any process that stops, prevents, or reduces the frequency, rate, or extent of non-canonical NF-kappaB signaling, a pathway centered on NIK, IKKalpha, and p52.
• The non-canonical NF-kappaB pathway is tightly controlled by negative regulators such as A20, which also modulates canonical NF-kappaB signaling.
• Deregulation of non-canonical NF-kappaB signaling contributes to hematological malignancies, including Hodgkin lymphoma, and to impaired immunity in disseminated tuberculosis [5, 8].
• The EDA2R-NIK axis has been implicated in cancer cachexia, highlighting the pathway's role beyond immune regulation.
• Negative regulation of non-canonical NF-kappaB signaling can be studied using knockout, point-mutation, knock-in, and overexpression cell models, combined with CRISPR library screening and bioinformatics [1, 6].
• Key negative regulators include A20 (TNFAIP3), TRIM9, and other proteins that interfere with NIK stabilization or p52-dependent transcription [2, 6].
Description
The non-canonical NF-kappaB signaling cascade is a distinct branch of NF-kappaB activation that relies on the stabilization of NF-kappaB-inducing kinase (NIK) and the processing of p100 into p52. Unlike the canonical pathway, which responds rapidly to inflammatory stimuli, the non-canonical pathway is slower and is critical for lymphoid organogenesis, B-cell maturation, and bone homeostasis. GO:1901223, negative regulation of non-canonical NF-kappaB signal transduction, encompasses all molecular events that attenuate this cascade, thereby preventing excessive or prolonged NF-kappaB activity [2, 6]. Negative regulation is essential because unchecked non-canonical NF-kappaB signaling drives oncogenesis and immune pathology. For example, A20 (TNFAIP3) is a well-characterized negative regulator that terminates NF-kappaB signaling, and its loss is associated with lymphomas. Similarly, brain-specific TRIM9 negatively regulates NF-kappaB activity, linking this process to neuroinflammation. Understanding how this negative regulation is achieved at the molecular level is crucial for developing targeted therapies. This article integrates authoritative QuickGO data with published literature to provide a comprehensive overview of GO:1901223, covering its definition, mechanisms, key genes, disease relevance, and experimental models. Researchers can use this information to design CRISPR-based studies that interrogate the negative regulation of non-canonical NF-kappaB signaling.
negative regulation of non-canonical NF-kappaB signal transduction At A Glance
| GO ID | GO:1901223 |
|---|---|
| GO term | negative regulation of non-canonical NF-kappaB signal transduction |
| Ontology | biological_process |
| Synonym | inhibition of NIK/NF-kappaB cascade; negative regulation of p52-dependent NF-kappaB signaling; downregulation of noncanonical NF-kappaB signaling |
| Major function | Attenuation of NIK-induced p100 processing and p52-dependent transcription |
| Key regulators | A20 (TNFAIP3), TRIM9, and other negative regulators [2, 6] |
| Associated diseases | Hodgkin lymphoma, cancer cachexia, disseminated tuberculosis [4, 5, 8] |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, library screening [1, 6] |
What Is GO:1901223?
GO:1901223, negative regulation of non-canonical NF-kappaB signal transduction, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the non-canonical NF-kappaB signaling cascade. This biological process includes mechanisms that inhibit NIK/NF-kappaB signaling, downregulate p52-dependent NF-kappaB signaling, or prevent NF-kappaB import into the nucleus. It is the opposite of positive regulation and serves to maintain immune homeostasis and prevent pathological NF-kappaB activation [2, 3].
Why Is negative regulation of non-canonical NF-kappaB signal transduction Important in Cell Biology?
Negative regulation of non-canonical NF-kappaB signaling is critical for preventing chronic inflammation and cancer. The non-canonical pathway is a key driver of immune cell survival and differentiation, and its dysregulation is linked to lymphomas, autoimmune diseases, and impaired immunity [3, 5, 8]. Understanding the negative regulators of this pathway provides insights into disease mechanisms and identifies potential therapeutic targets. For instance, A20-mediated negative regulation is a paradigm for how ubiquitin-editing enzymes control NF-kappaB. Moreover, the EDA2R-NIK axis in cancer cachexia demonstrates the pathway's systemic impact. Thus, studying GO:1901223 is essential for both basic immunology and translational medicine.
• Prevents excessive NF-kappaB activation that can lead to chronic inflammation and autoimmunity.
• Controls lymphoid organ development and B-cell maturation by fine-tuning p52 levels.
• Loss of negative regulators like A20 is associated with Hodgkin lymphoma and other B-cell malignancies [2, 5].
• Modulates immune responses in infectious diseases such as disseminated tuberculosis.
• Influences cancer cachexia through the EDA2R-NIK signaling axis.
• Provides targets for therapeutic intervention in inflammatory diseases and cancer [2, 6].
• Helps maintain neuroinflammation homeostasis via brain-specific regulators like TRIM9.
• Is essential for understanding the cross-talk between canonical and non-canonical NF-kappaB pathways.
• Enables the design of CRISPR screens to identify novel negative regulators.
• Supports the development of precision medicine approaches targeting NF-kappaB signaling.
What Happens During negative regulation of non-canonical NF-kappaB signal transduction?
Inhibition of NIK stabilization
In simple terms: Stopping the accumulation of the NIK protein, which is required to start the non-canonical pathway.
The non-canonical NF-kappaB pathway depends on the stabilization of NIK (NF-kappaB-inducing kinase). Negative regulation often involves the degradation of NIK through ubiquitin-proteasome systems. For example, A20 (TNFAIP3) negatively regulates NF-kappaB signaling by editing ubiquitin chains on signaling molecules, leading to NIK degradation. This prevents the downstream activation of IKKalpha and p100 processing.
Prevention of p100 processing
In simple terms: Blocking the conversion of p100 into p52, which is needed for the non-canonical pathway.
In the non-canonical pathway, NIK activates IKKalpha, which phosphorylates p100, leading to its partial proteasomal processing to p52. Negative regulation can inhibit this step by preventing IKKalpha activation or by enhancing the degradation of p100. A20 has been shown to interfere with this process, thereby reducing p52 generation.
Inhibition of p52-dependent transcription
In simple terms: Stopping the p52 protein from turning on genes in the nucleus.
Once p52 is generated, it translocates to the nucleus and activates transcription of target genes. Negative regulators can inhibit p52's transcriptional activity by promoting its nuclear export or degradation. TRIM9, a brain-specific tripartite motif protein, negatively regulates NF-kappaB activity, potentially by interfering with nuclear p52 function.
Modulation by deubiquitinases and ubiquitin ligases
In simple terms: Enzymes that add or remove ubiquitin tags to control pathway activity.
The non-canonical NF-kappaB pathway is heavily regulated by ubiquitination. A20 is a deubiquitinase that removes K63-linked ubiquitin chains from NIK, targeting it for degradation. Other ubiquitin ligases, such as TRAF3, also negatively regulate the pathway by promoting NIK degradation in resting cells. These enzymatic activities are central to GO:1901223.
Cross-regulation with canonical NF-kappaB
In simple terms: The two NF-kappaB pathways can influence each other's activity.
Negative regulators like A20 affect both canonical and non-canonical NF-kappaB signaling, indicating cross-talk. A20-mediated negative regulation of canonical NF-kappaB signaling also impacts non-canonical signaling by altering the availability of shared components. This interplay ensures balanced immune responses.
Key Genes Involved in GO:1901223 negative regulation of non-canonical NF-kappaB signal transduction
The following genes and proteins are key players in the negative regulation of non-canonical NF-kappaB signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFAIP3 (A20) | Deubiquitinase that negatively regulates NF-kappaB signaling by targeting NIK and other molecules | Loss is associated with lymphomas; target for CRISPR knockout studies |
| TRIM9 | Brain-specific E3 ubiquitin ligase that negatively regulates NF-kappaB activity | Implicated in neuroinflammation; potential target for neurodegeneration research |
| NIK (MAP3K14) | Central kinase of non-canonical NF-kappaB; its stabilization is inhibited by negative regulators | Key node for point mutations to study pathway activation |
| IKBKB (IKKbeta) | Kinase involved in canonical NF-kappaB; may cross-regulate non-canonical pathway | Target for knockout to dissect pathway specificity |
| NFKB2 (p100/p52) | Precursor protein processed to p52; negative regulation prevents its processing | Knock-in of tagged NFKB2 allows tracking of processing |
| TRAF3 | E3 ubiquitin ligase that promotes NIK degradation in resting cells | Knockout leads to constitutive non-canonical NF-kappaB activation |
| TRAF2 | Adapter protein that regulates NIK stability | Potential modifier of negative regulation |
| BIRC2 (cIAP1) | E3 ubiquitin ligase that targets NIK for degradation | Target for overexpression to enhance negative regulation |
| BIRC3 (cIAP2) | E3 ubiquitin ligase that targets NIK for degradation | Similar to cIAP1; knockout increases NIK levels |
| CYLD | Deubiquitinase that negatively regulates NF-kappaB signaling | Mutations linked to cylindromatosis; relevant to skin cancer |
| OTULIN | Deubiquitinase that regulates NF-kappaB | Potential negative regulator; knockout causes autoinflammation |
| NFKBIA (IkappaBalpha) | Inhibitor of canonical NF-kappaB; may affect non-canonical pathway | Overexpression can suppress NF-kappaB activity |
| REL | NF-kappaB subunit; not directly non-canonical but cross-regulates | Knockout affects immune cell development |
| RELB | Non-canonical NF-kappaB subunit that partners with p52 | Essential for non-canonical signaling; knockout abolishes pathway |
| MAP3K14 (NIK) | See NIK above | Central to pathway; negative regulation targets its stability |
| EDA2R | Receptor that activates NIK in cancer cachexia | Knockout reduces cachexia in models |
| TBK1 | Kinase that negatively regulates non-canonical NF-kappaB by targeting NIK | Overexpression inhibits pathway |
| IKBKE | Kinase with similar function to TBK1 | Potential negative regulator |
How Is negative regulation of non-canonical NF-kappaB signal transduction Regulated?
The negative regulation of non-canonical NF-kappaB signaling is itself tightly controlled. Key mechanisms include ubiquitination and deubiquitination of NIK and other pathway components. A20 (TNFAIP3) is a deubiquitinase that removes K63-linked ubiquitin chains from NIK, leading to its degradation. TRIM9, a brain-specific E3 ubiquitin ligase, negatively regulates NF-kappaB activity, possibly by targeting components of the pathway for degradation. Additionally, kinases such as TBK1 and IKKepsilon can phosphorylate NIK and promote its degradation. The balance between positive and negative regulators determines the duration and intensity of non-canonical NF-kappaB signaling.
negative regulation of non-canonical NF-kappaB signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFAIP3 (A20) | Hodgkin lymphoma, autoimmune diseases [2, 5] | Knockout in B-cell lines; overexpression in lymphoma cells |
| EDA2R | Cancer cachexia | Knockout mouse models; muscle cell overexpression |
| TRIM9 | Neuroinflammation | Brain-specific knockout; neuronal overexpression |
| NFKB2 | Immunodeficiency and lymphoma | Point mutation knock-in to mimic patient variants |
| MAP3K14 (NIK) | Cancer cachexia, lymphoma [4, 5] | Knock-in of degradation-resistant NIK |
Hodgkin lymphoma and other B-cell malignancies
Deregulation of non-canonical NF-kappaB signaling is a hallmark of Hodgkin lymphoma. Negative regulators such as A20 are frequently inactivated in these tumors, leading to constitutive NF-kappaB activation. Loss of A20-mediated negative regulation contributes to lymphomagenesis by allowing unchecked p52-dependent transcription. Understanding GO:1901223 provides insights into the molecular basis of Hodgkin lymphoma and identifies potential therapeutic targets.
Cancer cachexia
The EDA2R-NIK signaling axis has been implicated in cancer cachexia, a debilitating syndrome characterized by muscle wasting. Negative regulation of non-canonical NF-kappaB signaling may counteract cachexia by reducing NIK activity. Targeting this pathway could offer new strategies to treat cachexia in cancer patients.
Disseminated tuberculosis
Impaired T cell immunity in disseminated tuberculosis is associated with dysregulated non-canonical NF-kappaB signaling. Negative regulation of this pathway is crucial for maintaining appropriate immune responses. Modulating GO:1901223 could enhance host immunity against Mycobacterium tuberculosis.
Neuroinflammation
Brain-specific negative regulators like TRIM9 help control NF-kappaB activity in the central nervous system. Dysregulation of non-canonical NF-kappaB signaling has been linked to neuroinflammatory conditions. Enhancing negative regulation may be protective in neurodegenerative diseases.
From negative regulation of non-canonical NF-kappaB signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of A20 increase non-canonical NF-kappaB signaling? | TNFAIP3 knockout cell line (e.g., HEK293T) |
| Can TRIM9 negatively regulate NF-kappaB in neurons? | TRIM9 knockout primary neurons; overexpression in neuroblastoma |
| Does a point mutation in NIK affect its degradation? | NIK point-mutation knock-in (e.g., S340A) in cell lines |
| Can tagged p100 track processing to p52? | NFKB2 knock-in with HA or FLAG tag |
| Does overexpression of CYLD inhibit non-canonical NF-kappaB? | CYLD overexpression in lymphoma cell lines |
| What genes are essential for negative regulation? | Genome-wide CRISPR knockout library screening |
How to Study the negative regulation of non-canonical NF-kappaB signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function phenotypes for all genes | Identify novel negative regulators |
| RNA-seq | Transcriptional changes | Define gene expression downstream of negative regulators |
| Immunoprecipitation + mass spectrometry | Protein interactions and ubiquitination | Map NIK ubiquitination by A20 |
| Western blot | Protein levels of NIK, p100/p52 | Assess negative regulation of processing |
| Luciferase reporter assay | NF-kappaB transcriptional activity | Screen for inhibitors of non-canonical pathway |
| Fluorescence microscopy | Subcellular localization of p52 | Visualize nuclear import inhibition |
| CRISPR activation (CRISPRa) | Overexpression of candidate genes | Test if a gene negatively regulates the pathway |
| Bioinformatics pathway analysis | Enrichment of NF-kappaB signatures | Interpret RNA-seq data |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify novel negative regulators of non-canonical NF-kappaB signaling. By using a reporter of p52-dependent transcription, researchers can select for cells that lose negative regulation and thus have increased pathway activity. This approach has been used to uncover genes like A20 and TRIM9 [2, 6].
RNA sequencing (RNA-seq)
RNA-seq measures transcriptomic changes upon perturbation of candidate negative regulators. Knockout of A20 or TRIM9 leads to upregulation of NF-kappaB target genes, which can be quantified by RNA-seq [2, 6]. This method helps define the gene expression programs controlled by GO:1901223.
Proteomics and ubiquitination assays
Proteomic approaches can assess NIK stability and ubiquitination status. For example, immunoprecipitation followed by mass spectrometry can identify ubiquitination sites on NIK regulated by A20. These methods provide mechanistic insights into negative regulation.
Imaging and reporter assays
Live-cell imaging with fluorescently tagged p52 or NF-kappaB reporters allows real-time monitoring of non-canonical NF-kappaB activity. Overexpression of negative regulators like TRIM9 can be visualized to reduce nuclear translocation of p52. Such assays are valuable for high-content screening.
How CRISPR Can Be Used to Study GO:1901223 negative regulation of non-canonical NF-kappaB signal transduction
Knockout
CRISPR knockout of negative regulators such as TNFAIP3 (A20) or TRIM9 leads to hyperactivation of non-canonical NF-kappaB signaling. This approach is used to confirm the role of a gene in GO:1901223 and to study downstream effects on immune cell function and survival [2, 6].
Point Mutation
Point mutations can be introduced into key residues of NIK or p100 to study their regulation. For example, mutation of the NIK degradation motif prevents its ubiquitination, leading to constitutive pathway activation. Such models help dissect the molecular details of negative regulation.
Knock-in
Knock-in of tagged versions of NFKB2 (p100) or NIK allows tracking of protein processing and localization. This is useful for understanding how negative regulators affect p100 processing and p52 nuclear translocation.
Overexpression
Overexpression of candidate negative regulators, such as A20 or CYLD, can suppress non-canonical NF-kappaB signaling. This approach is used to test the sufficiency of a gene to inhibit the pathway and to identify potential therapeutic targets.
How EDITGENE Supports negative regulation of non-canonical NF-kappaB signal transduction Research
Researchers studying negative regulation of non-canonical NF-kappaB signal transduction-related genes often need to determine whether a candidate gene is causally involved in attenuating the pathway. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of non-canonical NF-kappaB signal transduction research.
Frequently Asked Questions About negative regulation of non-canonical NF-kappaB signal transduction
What is GO:1901223?
GO:1901223 is a Gene Ontology term for negative regulation of non-canonical NF-kappaB signal transduction, describing any process that stops or reduces the non-canonical NF-kappaB signaling cascade.
What genes are involved in negative regulation of non-canonical NF-kappaB signaling?
Key genes include TNFAIP3 (A20), TRIM9, TRAF3, BIRC2/3, CYLD, and TBK1, which act to degrade NIK or inhibit p100 processing [2, 3, 6].
How does A20 negatively regulate NF-kappaB?
A20 is a deubiquitinase that removes K63-linked ubiquitin chains from NIK, targeting it for degradation and thereby inhibiting non-canonical NF-kappaB signaling.
What diseases are associated with dysregulated non-canonical NF-kappaB signaling?
Diseases include Hodgkin lymphoma, cancer cachexia, disseminated tuberculosis, and neuroinflammatory conditions [4, 5, 6, 8].
What is the non-canonical NF-kappaB pathway?
It is a signaling cascade that relies on NIK stabilization and p100 processing to p52, leading to activation of p52/RelB dimers.
How can I study negative regulation of non-canonical NF-kappaB signaling?
You can use CRISPR knockout, point mutation, knock-in, overexpression, and library screening, combined with RNA-seq, proteomics, and imaging [1, 2, 6].
What is the role of TRIM9 in NF-kappaB signaling?
TRIM9 is a brain-specific E3 ubiquitin ligase that negatively regulates NF-kappaB activity, potentially by targeting pathway components for degradation.
Is there cross-talk between canonical and non-canonical NF-kappaB pathways?
Yes, negative regulators like A20 affect both pathways, and shared components allow cross-regulation.
What experimental models are available for studying GO:1901223?
Models include knockout cell lines, point-mutation knock-ins, tagged knock-ins, overexpression lines, and CRISPR library screens [1, 2, 3].
How does EDITGENE support research on non-canonical NF-kappaB?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to NF-kappaB research [1, 2, 6].
Conclusion
GO:1901223, negative regulation of non-canonical NF-kappaB signal transduction, is a critical biological process that maintains immune homeostasis and prevents pathological NF-kappaB activation. Key regulators such as A20 and TRIM9 have been identified, and their dysfunction is linked to lymphoma, cachexia, and infectious diseases [2, 4, 5, 6, 8]. Advances in CRISPR technology enable precise interrogation of these regulators, offering new avenues for therapeutic intervention. EDITGENE's comprehensive services empower researchers to dissect this pathway and translate findings into clinical applications.
References
- 1. Wang M et al.. 2021. Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice.. J Neuroinflammation 18(1):146 PMID: 34183019
- 2. Pujari R et al.. 2013. A20-mediated negative regulation of canonical NF-κB signaling pathway.. Immunol Res 57(1-3):166-71 PMID: 24242761
- 3. van Delft MA et al.. 2015. The contribution of NF-κB signalling to immune regulation and tolerance.. Eur J Clin Invest 45(5):529-39 PMID: 25735405
- 4. Agca S et al.. 2024. EDA2R-NIK signaling in cancer cachexia.. Curr Opin Support Palliat Care 18(3):126-131 PMID: 38801457
- 5. Weniger MA et al.. 2016. NF-κB deregulation in Hodgkin lymphoma.. Semin Cancer Biol 39:32-9 PMID: 27221964
- 6. Shi M et al.. 2014. Negative regulation of NF-κB activity by brain-specific TRIpartite Motif protein 9.. Nat Commun 5:4820 PMID: 25190485
- 8. Jiang J et al.. 2024. Disseminated tuberculosis is associated with impaired T cell immunity mediated by non-canonical NF-κB pathway.. J Infect 89(3):106231 PMID: 39032519
